Tarsus Pharmaceuticals, Inc. TARS Debt-to-equity

Debt-to-equity at other companies

AbbVieABBV

46.6×+38.6×

Bausch + LombBLCO

0.8×0.0×

Ocular TherapeutixOCUL

0.1×-0.2×

HRO

HarrowHROW

10.7×+2.6×

EyePoint, Inc.EYPT

0.1×0.0×

TTR

Turn Therapeutics Inc.TTRX

1×—

FAQ

What is Tarsus Pharmaceuticals, Inc.'s debt-to-equity?

Tarsus Pharmaceuticals, Inc. (TARS) reported debt-to-equity of 0.3× in Q2 2026.

How has Tarsus Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?

Tarsus Pharmaceuticals, Inc.'s debt-to-equity increased by 17.6% year-over-year, from 0.2× to 0.3×.

What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s debt-to-equity has grown at a 117.2% compound annual growth rate (CAGR), from 0× to 0.2×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.